Multiple Sclerosis: all 3,524 studies

Page 11 of 36. Open to participants first (668), then studies with results posted, then the rest; newest registration first within each.

• Dalfampridine for Imbalance in Multiple SclerosisCompletedNCT01444300Phase 2Results posted
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT01440101Phase 2/3Results posted
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionTerminatedNCT01436643Phase 4Results posted
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01433250Phase 2Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear CellsCompletedNCT01414634Phase 1/2Results posted
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01412333Phase 3Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on TeriflunomideCompletedNCT01403376Phase 2Results posted
• Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple SclerosisCompletedNCT01395316Phase 4Results posted
• Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple SclerosisCompletedNCT01357980Phase 2Results posted
• A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple SclerosisCompletedNCT01356940Phase 4Results posted
• Ampyra for Optic Neuritis in Multiple SclerosisCompletedNCT01337986Phase 2/3Results posted
• Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedNCT01333501Phase 4Results posted
• Long-Term Safety and Efficacy Study of Peginterferon Beta-1aCompletedNCT01332019Phase 3Results posted
• Study of Fampridine-ER Tablets in Patients With Multiple SclerosisCompletedNCT01328379Phase 3Results posted
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple SclerosisCompletedNCT01324232Phase 2Results posted
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedNCT01317004Phase 4Results posted
• Balance Training for People With Multiple Sclerosis Using Nintendo Wii FitCompletedNCT01299025Not applicableResults posted
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentCompletedNCT01285401Phase 2Results posted
• A Pilot Study of Lithium in Progressive Multiple SclerosisCompletedNCT01259388Phase 1/2Results posted
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-betaTerminatedNCT01252355Phase 3Results posted
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01247324Phase 3Results posted
• Lubiprostone in Patients With Multiple Sclerosis Associated ConstipationCompletedNCT01236534Phase 4Results posted
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01226745Phase 2Results posted
• Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis PatientsCompletedNCT01225289Phase 4Results posted
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01216072Phase 4Results posted
• Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple SclerosisCompletedNCT01214317Not applicableResults posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)CompletedNCT01207648Results posted
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01201356Phase 3Results posted
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis PatientsCompletedNCT01201343Phase 4Results posted
• Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT01199861Phase 3Results posted
• Telehealth-Based Exercise Program to Treat Fatigue in MSCompletedNCT01198977Not applicableResults posted
• A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyCompletedNCT01198132Phase 2Results posted
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisCompletedNCT01194570Phase 3Results posted
• Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)CompletedNCT01188811Phase 2/3Results posted
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01185821Phase 2Results posted
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT01167426Phase 3Results posted
• Zoledronic Acid in MS-patients With OsteoporosisTerminatedNCT01166178Phase 3Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• Natalizumab De-escalation With Interferon Beta-1bCompletedNCT01144052Phase 4Results posted
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedNCT01142466Phase 4Results posted
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]TerminatedNCT01134627Phase 2Results posted
• Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug DeliveryCompletedNCT01117090Results posted
• A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
• ATX-MS-1467 in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01097668Phase 1Results posted
• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01093326Phase 2Results posted
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialCompletedNCT01085318Phase 4Results posted
• Tysabri Effects on Cognition and Neurodegeneration in Multiple SclerosisCompletedNCT01071512Not applicableResults posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedNCT01067521Phase 3Results posted
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01064401Phase 3Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• POC-MD MRI-based Trial in Relapsing-remitting Multiple SclerCompletedNCT01051817Phase 2Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT01051349Phase 2Results posted
• A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple SclerosisTerminatedNCT01047319Phase 3Results posted
• Patient Research Cohort: Rapidly Evolving Multiple SclerosisCompletedNCT01044576Results posted
• Effects of Vaporized Marijuana on Neuropathic PainCompletedNCT01037088Phase 1/2Results posted
• A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use StudyCompletedNCT01036165Phase 3Results posted
• The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics TrialCompletedNCT01034579Phase 4Results posted
• Effects of Training on Central Auditory Function in Multiple SclerosisCompletedNCT01023074Not applicableResults posted
• Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical TrialsCompletedNCT01013350Results posted
• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01006265Phase 2Results posted
• Defining the Anti-inflammatory Role of Lipoic Acid in Multiple SclerosisCompletedNCT00997438Phase 1Results posted
• A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease CourseTerminatedNCT00988052Phase 3Results posted
• Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)CompletedNCT00981084Phase 2/3Results posted
• Escitalopram (Lexapro) for Depression MS or ALSCompletedNCT00965497Phase 3Results posted
• The Multicenter, Open-label, Single-use Autoinjector Convenience StudyCompletedNCT00958009Phase 3Results posted
• Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic TremorCompletedNCT00954421Not applicableResults posted
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)CompletedNCT00950248Phase 1/2Results posted
• Safety of New Formulation of Glatiramer AcetateCompletedNCT00947752Phase 3Results posted
• Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis SubjectsCompletedNCT00938366Phase 1Results posted
• Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)CompletedNCT00937157Not applicableResults posted
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabCompletedNCT00930553Phase 3Results posted
• Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder DysfunctionTerminatedNCT00913510Not applicableResults posted
• Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisCompletedNCT00906399Phase 3Results posted
• A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple SclerosisCompletedNCT00883337Phase 3Results posted
• A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT00882999Phase 2Results posted
• Rivastigmine in Multiple Sclerosis Patients With Cognitive ImpairmentTerminatedNCT00881205Phase 4Results posted
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00879658Phase 2Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00870740Phase 2Results posted
• Expiratory Muscle Training for Persons With Neurodegenerative DiseaseCompletedNCT00856518Phase 2/3Results posted
• Atacicept in Multiple Sclerosis Extension Study, Phase IITerminatedNCT00853762Phase 2Results posted
• Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple SclerosisCompletedNCT00841321Phase 2Results posted
• Safety of Polyphenon E in Multiple Sclerosis Pilot StudyCompletedNCT00836719Phase 1Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis SubjectsCompletedNCT00828204Phase 3Results posted
• Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)CompletedNCT00813709Phase 3Results posted
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisCompletedNCT00811395Phase 2Results posted
• Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00803049Phase 3Results posted
• Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsTerminatedNCT00784836Phase 3Results posted
• Rehabilitation Study in MS PatientsTerminatedNCT00780455Phase 4Results posted
• Duloxetine for Multiple Sclerosis PainCompletedNCT00755807Phase 3Results posted
• American Ginseng Treatment for Multiple Sclerosis Related FatigueCompletedNCT00754832Phase 2Results posted
• An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisCompletedNCT00751881Phase 3Results posted
• An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseTerminatedNCT00745615Phase 2Results posted
• 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.CompletedNCT00735007Phase 3Results posted

← Multiple Sclerosis overview